Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Profits Dive 31% at AstraZeneca

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

LONDON -- Shares of AstraZeneca (LSE: AZN  ) (NYSE: AZN  )  dropped 1% to 3,353 pence during early London trade this morning after the FTSE 100 member reported first-quarter sales falling 13% to $6.4 billion.

AstraZeneca, the world's fifth-largest pharmaceutical group, revealed profits for the quarter had declined 31% to $1 billion, compared to $1.6 billion last year. Core operating margins fell from 40.8% to 36.4%.

The company confirmed that the "key drivers" for the revenue shortfall were anticipated expiry of patents and the loss of exclusivity in certain markets of major anti-psychotic and heart medicines. While emerging-market revenues increased by 9%, this performance was more than offset by U.S. and European sales falling 16%.

Looking ahead, AstraZeneca revealed it expected group profits to "decline at a rate that is significantly higher than the decline in revenue in 2013," while maintaining current sales expectations.

Chief executive Pascal Soriot commented:

As anticipated, the first quarter performance reflects the loss of exclusivity for several large products. We remain focused on our strategic priorities of returning to growth and achieving scientific leadership."

"Brilinta, the diabetes franchise, Emerging Markets, Japan and our Respiratory products have all made good progress and we continued to invest in distinctive science that will advance our knowledge of disease physiology and help to identify new drug targets.

The company will hold its annual general meeting later today, where shareholders are expected to vote on Soriot's $11 million pay package.

With a market cap of 42 billion pounds, AstraZeneca is valued at around 9.8 times expected earnings and offers an impressive prospective dividend yield of 5.5%.

While that yield might appear attractive, there aren't many global companies whose dividend can match the long-term stability or visibility laid out by "The Motley Fool's Top Income Stock for 2013."

In fact, the Fool's choice recently revealed its dividend would increase at least in line with the rate of U.K. inflation for the foreseeable future and provides a market-beating 5.1% yield.

Just click here to download the free exclusive report.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2387449, ~/Articles/ArticleHandler.aspx, 9/29/2016 3:10:30 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 12:12 PM
AZN $5138.80 Up +16.80 +0.00%
AstraZeneca CAPS Rating: No stars
AZN $33.82 Up +0.21 +0.62%
AstraZeneca CAPS Rating: ****